Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Losartan may be effective in treating patients with idiopathic pulmonary fibrosis.

PURPOSE: This clinical trial is studying the side effects of losartan and to see how well it works in treating patients with idiopathic pulmonary fibrosis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of South Florida
• Collaborator: National Cancer Institute (NCI)
• Treatments: Losartan

Criteria

INCLUSION CRITERIA:

• Age > 21 years

• Diagnosis of idiopathic pulmonary fibrosis

• Patients taking Coumadin and/or N-acetylcysteine may participate in the study

• Baseline forced vital capacity (FVC) must be greater than or equal to 50%

• Baseline 6 minute walk test distance walked must be greater than or equal to 200 meters not requiring greater than 6 lpm of oxygen

EXCLUSION CRITERIA:

• Pregnant, intending to become pregnant or breastfeeding

• Current or previous smoker of cigarettes or marijuana that recently quit within the last 6 months prior to enrollment

• Allergy or allergic reaction to Losartan or any other angiotensin II receptor blocker

• Taking losartan or any other angiotensin II receptor blocker

• Baseline systolic blood pressure < 100 mmHg

• Currently taking or has taken immunosuppressant agents within the last month such as azathioprine, cyclophosphamide, colchicine and/or prednisone

• History of lung transplant

• History of kidney failure or liver disease

• Inability to attend clinic visits